DS
GRTX

David Shaw’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History

David Shaw’s Portfolio GRTX Stock Details GRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-37,693
Closed -$90K – 5900
2022
Q1 		$90K Buy
+37,693
New +$98.2K ﹤0.01% 5016

Other funds holding GRTX

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

David Shaw's GRTX Position: Q2 2022 in Review

David Shaw sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2022, closing a stake of 37,693 shares — an estimated $90K sold.

David Shaw first reported a position in GRTX in Q1 2022 and held it in 1 quarter. The position peaked at $90K in Q1 2022. 39 funds tracked by Wall St. Rank hold GRTX as of Q2 2022.

  • David Shaw reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 37,693 Galera Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $90K.
  • David Shaw first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • David Shaw's Galera Therapeutics, Inc. Common Stock position peaked at $90K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.